|
|
| Line 1: |
Line 1: |
| [[Image:1qxq.jpg|left|200px]] | | {{Seed}} |
| | [[Image:1qxq.png|left|200px]] |
|
| |
|
| <!-- | | <!-- |
| Line 9: |
Line 10: |
| {{STRUCTURE_1qxq| PDB=1qxq | SCENE= }} | | {{STRUCTURE_1qxq| PDB=1qxq | SCENE= }} |
|
| |
|
| '''STRUCTURE OF AN INDOLICIDIN PEPTIDE DERIVATIVE WITH HIGHER CHARGE'''
| | ===STRUCTURE OF AN INDOLICIDIN PEPTIDE DERIVATIVE WITH HIGHER CHARGE=== |
|
| |
|
|
| |
|
| ==Overview==
| | <!-- |
| Indolicidin is an antimicrobial cationic peptide with broad-spectrum activity isolated from bovine neutrophils. An indolicidin analogue CP-11, ILKKWPWWPWRRK-NH(2), with improved activity against Gram-negative bacteria had increased positive charge and amphipathicity while maintaining the short length of the parent molecule. The structure of CP-11 in the presence of dodecylphosphocholine (DPC) micelles was determined using nuclear magnetic resonance spectroscopy. CP-11 was found to be an amphipathic molecule with a U-shaped backbone bringing the N- and C-termini in close proximity. On the basis of this close proximity, a cyclic disulfide-bonded peptide cycloCP-11, ICLKKWPWWPWRRCK-NH(2), was designed to stabilize the lipid-bound structure and to increase protease resistance. The three-dimensional structure of cycloCP-11 was determined under the same conditions as for the linear peptide and was found to be similar to CP-11. Both CP-11 and cycloCP-11 associated with phospholipid membranes in a similar manner as indicated by circular dichroism and fluorescence spectra. The minimal inhibitory concentrations of CP-11 and cycloCP-11 for a range of bacteria differed by no more than 2-fold, and they were nonhemolytic at concentrations up to 256 microg/mL. Cyclization was found to greatly increase protease stability. The half-life of cycloCP-11 in the presence of trypsin was increased by 4.5-fold from 4 to 18 min. More importantly, the antibacterial activity of cycloCP-11, but not that of CP-11, in the presence of trypsin was completely retained up to 90 min since the major degradation product was equally active. A structural comparison of CP-11 and cycloCP-11 revealed that the higher trypsin resistance of cycloCP-11 may be due to the more compact packing of lysine and tryptophan side chains. These findings suggest that cyclization may serve as an important strategy in the rational design of antimicrobial peptides.
| | The line below this paragraph, {{ABSTRACT_PUBMED_14640680}}, adds the Publication Abstract to the page |
| | (as it appears on PubMed at http://www.pubmed.gov), where 14640680 is the PubMed ID number. |
| | --> |
| | {{ABSTRACT_PUBMED_14640680}} |
|
| |
|
| ==About this Structure== | | ==About this Structure== |
| 1QXQ is a [[Single protein]] structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1QXQ OCA]. | | 1QXQ is a [[Single protein]] structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1QXQ OCA]. |
|
| |
|
| ==Reference== | | ==Reference== |
| Line 26: |
Line 30: |
| [[Category: Rozek, A.]] | | [[Category: Rozek, A.]] |
| [[Category: Extended beta structure with two bend]] | | [[Category: Extended beta structure with two bend]] |
| ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 06:49:44 2008'' | | |
| | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 16:15:34 2008'' |